MedCath sells ownership interest, management agreement in Coastal Carolina Heart to North Carolina hospital

NewsGuard 100/100 Score

MedCath Corporation (Nasdaq: MDTH) announced today it has completed the sale of its ownership interest and management agreement in Coastal Carolina Heart to New Hanover Regional Medical Center (Wilmington, North Carolina). Coastal Carolina Heart is a component of the Company's MedCath Partners division and provides certain catheterization laboratory management services to New Hanover Regional Medical Center.  

Pursuant to transaction terms, MedCath received $5.0 million for its 9.2% ownership interest and management agreement in Coastal Carolina Heart.  MedCath will also receive, over the next several months, it's pro rata share of the additional funds from the liquidation of the venture's working capital. MedCath anticipates that it will retain approximately $4.0 million from the transaction, after closing costs and taxes.  Today's transaction is in addition to yesterday's related announcement that MedCath sold a significant portion of MedCath Partners operations valued at $25.0 million. MedCath anticipates retaining approximately $16.0 million from that transaction after collection of retained accounts receivable, payment of known liabilities, closing costs and taxes.

Source:

MedCath Corporation

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
SGLT2 inhibitors: A game-changer in preventing heart failure and sudden cardiac deaths